Galderma has devised a system to help you identify exactly what is wrong with your face. Using a scale of zero to three, the Swiss injectables maker grades the severity of sagging, wrinkles and asymmetry. Keywan Taghetchian, a Zurich‑based doctor who trains practitioners on how to use Galderma’s treatments, asserts that “beauty is very objective”.

The company is one of the prime beneficiaries of the normalisation of “tweakments” like botox and filler. Sales of its injectables rose 11.5% to $2.5bn in 2025, with clinics becoming a fixture of high streets and shopping malls. Hollywood actors appear to have stopped ageing, and doctors‑turned‑influencers tout new procedures on social media.

But the surge in demand comes with risks. Galderma exerts little control over who administers its products, exposing it to unwanted side effects such as swelling or a crooked smile. Naveen Cavale of ISAPS called the injector industry a “wild west”, and Galderma is racing to train the fast‑growing ranks of doctors, dentists and nurses.

Founded in 1981 as a joint venture between L’Oréal and Nestlé, Galderma went public in 2024 after a five‑year period under EQT. Its shares have more than doubled, and it is now the world’s second‑largest injectables maker after Abb Vie, with a market capitalisation of about SFr 41bn ($50bn). Analysts expect $1.1bn pre‑tax profit on $6.3bn revenue this year, a 21% rise.